Status:
COMPLETED
Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients
Lead Sponsor:
AbbVie
Conditions:
Non-infectious Intermediate, Posterior and Panuveitis
Eligibility:
All Genders
19-99 years
Brief Summary
The objective of this study is to evaluate the safety and effectiveness of Humira® (Adalimumab) for the treatment of non-infectious intermediate, posterior, or panuveitis patients under a routine trea...
Eligibility Criteria
Inclusion
- Patient has been diagnosed with Non-infectious intermediate, posterior and pan-uveitis
- Patients voluntarily signed a patient authorization \& informed consent form.
- Decision on the treatment with Humira® was made prior to any decision to approach the patient to participate in this study.
- Humira® treatment is indicated as per local Summary of Product Characteristics (SmPC) and professional and/or reimbursement guidelines.
Exclusion
- A patient who are contraindications to originator adalimumab (Humira®) as listed on the approved Korean label.
- A patient who is participating on other interventional clinical trials
- Prior treatment with Humira®, including current course of Humira® started prior to baseline visit assessments.
Key Trial Info
Start Date :
January 25 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 16 2020
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT03339102
Start Date
January 25 2018
End Date
July 16 2020
Last Update
July 19 2021
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusan National University Hosp /ID# 202026
Busan, Busan Gwang Yeogsi, South Korea, 49241
2
Soon Chun Hyang University Cheonan Hospital /ID# 204551
Cheonan, Chungcheongnam-do, South Korea, 31151
3
Yeungnam University Med Ctr /ID# 201361
Daegu, Daegu Gwang Yeogsi, South Korea, 42415
4
Seoul National Univ Bundang ho /ID# 201657
Seongnam, Gyeonggido, South Korea, 13620